[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 50.16.107.222. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Viewpoint
August 2014

Inadequacy of Clinical Trial Designs and Data to Control for the Confounding Impact of Race/Ethnicity in Response to Treatment in Multiple Sclerosis

Author Affiliations
  • 1Cape Neurology Specialists, St Francis Medical Center, Cape Girardeau, Missouri
JAMA Neurol. 2014;71(8):943-944. doi:10.1001/jamaneurol.2014.79

Multiple sclerosis (MS) is an autoimmune demyelinating disease characterized by a complex mix of genetics and gene-environment interactions. As compared with white Americans, African Americans are thought to have a lower risk for developing MS but a greater risk of disability and more opticospinal MS. Data show that MS in African Americans follows a more severe course than in white Americans. The 6-tiered multiple sclerosis severity scale–based analysis demonstrates that African ancestry is a risk factor for a more rapidly disabling disease course.1 While MS is rare in native Africans, it can be associated with a higher risk of cane dependency, a shorter time to cane, and a shorter duration from symptom onset to diagnosis.2 In one study, African American patients with MS admitted to US nursing homes were 6 years younger than white American patients with MS on admission, but more disabled.3

First Page Preview View Large
First page PDF preview
First page PDF preview
×